

Food Allergy FDA Approvals, Clinical Trials, Pipeline Insights, Companies |

Food Allergy Pipeline

LAS VEGAS, NV, UNITED STATES, February 5, 2025 /EINPresswire.com/ -- "DelveInsight's, "Food Allergy Pipeline Insight" report provides comprehensive insights about 25+ companies and 30+ pipeline drugs in Food Allergy pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

□ Stay ahead in the Food Allergy treatment landscape! Explore the latest breakthroughs, emerging therapies, and key players shaping the market. Download the report now! @ [Food Allergy Pipeline Outlook](#)

Key Takeaways from Food Allergy Pipeline Report

- In January 2025:- ALK-Abelló A/S:- This is a phase I/II, dose-escalation, multi-site trial including subjects with peanut allergy confirmed by screening double-blind, placebo-controlled food challenge. The trial is conducted in 3 parts; part 1 will determine the entry dose of the up-dosing regimen (UDR) in adults and adolescents; part 2 will characterize the tolerability of the up-dosing regimen in adults, adolescents and children; part 3 will evaluate the efficacy of 2 maintenance doses of the SLIT-tablet primarily in adolescents and children; a small number of adults may also be included.
- In January 2025:- National Institute of Allergy and Infectious Diseases (NIAID)- This study is a multi-center, randomized, double-blind, placebo-controlled study in participants 1 to less than 56 years of age who are allergic to peanut and at least two other foods (including milk, egg, wheat, cashew, hazelnut, or walnut). While each participant may be allergic to more than two other foods, the primary endpoint/outcome in this study will only be assessed in peanut and two other foods for each participant.
- DelveInsight's Food Allergy pipeline report depicts a robust space with 25+ active players working to develop 30+ pipeline therapies for Food Allergy treatment.
- The leading Food Allergy Companies such as Novartis Pharmaceuticals, Alladapt Immunotherapeutics, Inc., Carsten Bindslev-Jensen, DBV Technologies, Aimmune Therapeutics, Inc., and others.
- Promising Food Allergy Therapies such as Ligelizumab 120 mg, Acalabrutinib, Dupilumab, Omalizumab, and others.

□ Unlock strategic insights into the evolving Food Allergy pipeline! Get in-depth analysis of clinical-stage developments and upcoming therapies. Access the full report today! @ [Food Allergy Clinical Trials](#)

Food Allergy Emerging Drugs Profile

- Viaskin Peanut: DBV Technologies

Viaskin Peanut (DBV712) is the novel product candidate, which is based on epicutaneous immunotherapy (EPIT), a proprietary technology platform that delivers biologically active compounds to the immune system through the skin. Viaskin is based on epicutaneous immunotherapy, or EPIT[®], DBV's method of delivering biologically active compounds to the immune system through intact skin. The Viaskin patch contains a deposit of dry allergen at its center that sits above the skin on a backing film. When the patch is applied to intact skin, a condensation chamber is formed between the allergen and the top layer of skin, the epidermis. Natural water loss from the skin accumulates within the condensation chamber, solubilizing the allergen. The drug is currently being investigated in the Preregistration stage of development for the treatment of peanut allergy.

- PVX-108: Aravax

PVX108 is a next-generation, allergen-specific immunotherapy using peptides that represent critical fragments of peanut proteins to precisely target the T cells driving peanut allergy. Administered once per month, therapy is designed to precisely induce tolerance to peanut protein without the safety concerns constraining the use of the only registered therapy which uses natural extracts from peanuts. The presence of whole peanut allergens in those extracts exposes patients to significant risks of anaphylaxis. Previously, a randomized, double-blind, placebo-controlled Phase I trial in 66 peanut-allergic adults (AVX-001) showed no evidence of adverse events of clinical concern. Additionally, ex vivo studies providing a surrogate measure of safety (basophil activation) in 185 peanut-allergic blood donors confirmed a lack of basophil reactivity to PVX108 in contrast to peanut extract. These data demonstrate that PVX108 has a highly favourable safety profile for treatment of peanut allergic patients, including those with severe allergy. The drug is currently being investigated in the Phase II stage of development for the treatment of peanut allergy.

- AIMab7195: Xencor

AIMab7195 is an anti-IgE monoclonal antibody with enhanced binding to the Fc gamma receptor IIb (FcγRIIb). IgE recognizes and interacts with allergens and, as a result, can activate immune cells, such as mast cells and basophils that drive an allergic response in patients. AIMab7195 is designed to clear IgE rapidly from circulation, to prevent the production of IgE by preventing the activation of IgE-positive B cells, and to block IgE from interacting with its receptor on immune cells. AIMab7195 has been evaluated in two Phase I studies that enrolled more than 100 healthy volunteers and patients with allergy and atopic disease. The drug is currently being investigated in the Phase I stage of development for the treatment of peanut allergy.

□ Gain a competitive edge in the Food Allergy market! Discover promising pipeline candidates, regulatory trends, and future treatment outlooks. Request your report now! @ [Food Allergy Unmet Needs](#)

Food Allergy Companies

Novartis Pharmaceuticals, Alladapt Immunotherapeutics, Inc., Carsten Bindslev-Jensen, DBV Technologies, Aimmune Therapeutics, Inc., and others.

Food Allergy pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

- Intravenous
- Subcutaneous
- Oral
- Intramuscular

Food Allergy Products have been categorized under various Molecule types such as

- Monoclonal antibody
- Small molecule
- Peptide

Dive into comprehensive Food Allergy pipeline analysis, key company strategies, and clinical advancements. Download DelveInsight's exclusive report! @ Food Allergy FDA Approvals and Pipeline Developmental Activities- https://www.delveinsight.com/sample-request/food-allergy-pipeline-insight?utm_source=einpresswire&utm_medium=pressrelease&utm_campaign=ypr

Scope of the Food Allergy Pipeline Report

- Coverage- Global
- Food Allergy Companies- Novartis Pharmaceuticals, Alladapt Immunotherapeutics, Inc., Carsten Bindslev-Jensen, DBV Technologies, Aimmune Therapeutics, Inc., and others.
- Food Allergy Therapies- Ligelizumab 120 mg, Acabrutinib, Dupilumab, Omalizumab, and others.
- Food Allergy Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
- Food Allergy Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III

□ Track the latest innovations in Food Allergy therapies! Stay informed on upcoming launches, trial results, and market dynamics. Get your copy of the report today! @ Food Allergy Market Drivers and Barriers, and Future Perspectives- https://www.delveinsight.com/sample-request/food-allergy-pipeline-insight?utm_source=einpresswire&utm_medium=pressrelease&utm_campaign=ypr

Table of Content

1. Introduction
2. Executive Summary
3. Food Allergy: Overview
4. Pipeline Therapeutics
5. Therapeutic Assessment
6. Food Allergy- DelveInsight's Analytical Perspective
7. Late Stage Products (Preregistration)
8. Viaskin Peanut: DBV Technologies
9. Drug profiles in the detailed report.....
10. Mid Stage Products (Phase II)
11. PVX-108: Aravax
12. Drug profiles in the detailed report.....
13. Early Stage Products (Phase I)
14. AIMab7195: Xencor
15. Drug profiles in the detailed report.....
16. Preclinical and Discovery Stage Products
17. Drug Name: Company Name
18. Drug profiles in the detailed report.....
19. Inactive Products
20. Food Allergy Key Companies
21. Food Allergy Key Products
22. Food Allergy- Unmet Needs
23. Food Allergy- Market Drivers and Barriers
24. Food Allergy- Future Perspectives and Conclusion
25. Food Allergy Analyst Views
26. Food Allergy Key Companies
27. Appendix

List of Top Selling Market Research Reports in 2025

Surgical Lasers Market - <https://www.delveinsight.com/report-store/surgical-lasers-market>

Intraocular Lens Market - <https://www.delveinsight.com/blog/top-companies-in-the-intraocular-lens-market>

Myeloproliferative Neoplasms Market - <https://www.delveinsight.com/report-store/myeloproliferative-neoplasms-market>

Skin Neoplasm Market - <https://www.delveinsight.com/report-store/nonmelanoma-skin-cancer-market>

Healthcare Competitive Benchmarking - <https://www.delveinsight.com/consulting/competitive-benchmarking-services>

Microscopy Device Market - <https://www.delveinsight.com/report-store/microscopy-device-market>

Pacemakers Market - <https://www.delveinsight.com/report-store/pacemakers-market>

Urea Cycle Disorders Market - <https://www.delveinsight.com/blog/urea-cycle-disorder-market>
Novel Drug Delivery Devices Market - <https://www.delveinsight.com/report-store/novel-drug-delivery-devices>
Nk Cell Therapy Market - <https://www.delveinsight.com/infographics/nk-cell-therapy-market>
Surgical Mask & Respirator Market - <https://www.delveinsight.com/report-store/surgical-mask-respirator-market>
Lymphoedema Market - <https://www.delveinsight.com/report-store/lymphoedema-market>
Phototherapies For Psoriasis Market - <https://www.delveinsight.com/report-store/phototherapy-devices-market>
Sepsis Market - <https://www.delveinsight.com/report-store/sepsis-market>
Bone Growth Stimulator Market - <https://www.delveinsight.com/report-store/bone-growth-stimulators-market>
Antibody Drug Conjugate Market - <https://www.delveinsight.com/report-store/antibody-drug-conjugate-market>
Overactive Bladder Syndrome Market - <https://www.delveinsight.com/report-store/underactive-bladder-market>
Medical Marijuana Market - <https://www.delveinsight.com/report-store/medical-marijuana-market>
Lactose Intolerance Market - <https://www.delveinsight.com/report-store/lactose-intolerance-market>
Catheter Stabilization Devices Market - <https://www.delveinsight.com/sample-request/catheter-stabilization-securement-device-market>
Dyspepsia Market - <https://www.delveinsight.com/report-store/functional-dyspepsia-pipeline-insight>
Total Knee Arthroplasty Market - <https://www.delveinsight.com/report-store/knee-reconstruction-devices-market>

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Yash Bhardwaj
DelveInsight
+91 9650213330
[email us here](#)

This press release can be viewed online at: <https://www.einpresswire.com/article/783200125>

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something

we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information.

© 1995-2025 Newsmatics Inc. All Right Reserved.